OBJECTIVE: The incidence of @entity263 is rising rapidly in Sweden and there is a need to better understand the pattern of diagnosis, @entity5 characteristics and treatment. MATERIAL AND METHODS: Between 1996 and 2005, all new cases of @entity263 were intended to be registered in the National @entity263 Register (NPCR). This register contains information on diagnosing unit, date of diagnosis, cause of diagnosis, @entity5 grade, @entity5 stage according to the TNM classification in force, serum @entity1486 (PSA) levels at diagnosis and primary treatment given within the first 6 months after diagnosis. RESULTS: In total, 72,028 @entity1 were registered, comprising >97% of all pertinent incident cases of @entity263 in the Swedish @entity5 Register (SCR). During the study period there was a considerable decrease in median age at the time of diagnosis, a stage migration towards smaller @entity5 , a decrease in median serum PSA values at diagnosis, a decrease in the age-standardized incidence rate of @entity1 diagnosed with distant metastases or with a PSA level of > 100 ng/ml at diagnosis and an increase in the proportion of @entity5 with Gleason score <6. Relatively large geographical differences in the median age at diagnosis and the age-standardized incidence of cases with category T1c @entity5 were observed. Treatment with curative intent increased dramatically and treatment patterns varied according to geographical region. In @entity1 with localized @entity5 and a PSA level of <20 ng/ml at diagnosis, expectant treatment was more commonly used in those aged > or =75 years than in those aged <75 years. Also, the pattern of endocrine treatment varied in different parts of Sweden. CONCLUSIONS: All changes in the register seen over time are consistent with increased diagnostic activity, especially PSA testing, resulting in an increased number of cases with @entity66 , predominantly @entity5 in category T1c. The patterns of diagnosis and treatment of @entity263 vary considerably in different parts of Sweden. The NPCR continues to be an important source for research, epidemiological surveillance of the incidence, diagnosis and treatment of @entity263 .

Clinical characteristics and primary treatment of XXXX in Sweden between 1996 and 2005.

@entity1 :: ('9606', 'Species') :: ['men', 'patients'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer', 'adenocarcinoma of the prostate gland', 'Prostate Cancer'] @entity66 :: ('MESH:D004194', 'Disease') :: ['early disease'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors', 'Cancer'] @entity1486 :: ('354', 'Gene') :: ['prostate-specific antigen']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
